Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights
EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use of Cosentyx to treat their patients with psoriatic arthritis (PsA). Nonetheless, this increasing user base has not translated into overall increases in biologic share. Furthermore, in Q2 2016, rheumatologists anticipated doubling their Cosentyx share over the subsequent six month period, a projection that panned out and was fully realized in practice. However, since the end of 2016, rheumatologists have continued to forecast positive Cosentyx growth, but have failed to see those projections through.
The majority of rheumatologists indicate that “ideal” Cosentyx patients have previously failed at least one TNF agent, a group representing nearly half of all biologic-treated PsA patients, so what is at the source of Cosentyx’s apparent plateau? Just under one-third of rheumatologists report high satisfaction with the IL-17 inhibitor, a lower percent compared to the leading TNF agents and Janssen’s Stelara. Furthermore, despite Cosentyx’s association with strong efficacy in skin clearance, more rheumatologists prefer AbbVie’s Humira over Cosentyx for patients with severe psoriasis. Finally, use of Cosentyx continues to be hampered by rheumatologists’ perceptions of inferior market access compared to more established biologic brands.
Additional pressure on Cosentyx is ahead in the form of pipeline PsA agents which will offer even more options for non-TNF treatment. Among those is the second IL-17 inhibitor, Eli Lilly’s Taltz. Although nearly one-third of respondents see Cosentyx’s first-to-market status as a significant advantage over Taltz, over the past year there has been a significant increase in Taltz familiarity and a growing percent of rheumatologists anticipate routine use of Taltz once approved.
Taltz is expected to have a competitive position in the PsA treatment paradigm if available, however most rheumatologists agree that there is a higher unmet need for new, oral, small molecule agents for PsA than for any additional alternate MOA biologics. Indeed, when asked directly which agent they would most like to see gain the PsA indication, 61% selected a JAK inhibitor, such as Pfizer’s Xeljanz, whereas the remaining respondents were split between BMS’ Orencia, an additional IL-17 such as Taltz, and an IL-23 inhibitor. According to RealWorld Dynamix™: Biologic and Otezla Switching in PsA, which evaluated over 1000 PsA patients recently switched from one biologic or Otezla to a different brand, Xeljanz has already captured 2% of the switch population and one in five recently switched patients are considered by the treating rheumatologist to be good candidates for future treatment with Xeljanz.
RealTime Dynamix: Psoriatic Arthritis is an independent report series published on a quarterly basis. The series tracks the evolution of the PsA market, provides a deep dive on launch effectiveness, and highlights opportunities for pipeline agents. The next wave of research will be published in September 2017.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company specializing in renal, autoimmune, neurologic and rare disease markets. We provide clients with strategic insights leveraged from our independent studies conducted with healthcare providers and other stakeholders.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Lynn Price, Immunology Franchise Head
To view media coverage of this release, click here.